Fraunhofer-Institut für Zelltherapie und Immunologie IZI Fraunhofer Institute for Cell Therapy and Immunology IZI
Fraunhofer Institute for Cell Therapy and Immunology IZI
  • Contact
  • Press / media
  • Jobs / career
  • Sitemap
  • Deutsch
  • About us
    [X] About us
    • Institute in numbers
    • Organization structure
    • Research networks
    • Director
    • Advisory board
    • Contact persons for customers and partners
  • Research areas
  • Departments
    [X] Departments
    • Leipzig location
      • Department of GMP Cell and Gene Therapy
      • Department of Cell and Gene Therapy Development
        • Cell and Molecular Biology
        • NK Cell Technologies
        • In Vivo Models
        • GMP Development
        • GMP Biopharmaceuticals
        • Clinical Gene Transfer
      • Department of Preclinical Development and Validation
      • Department of Infection Research and Diagnostics
        • Vaccine Technologies
        • Preclinical Validation
        • Antimicrobial Biotechnology
        • Experimental Imaging
        • MicroDiagnostics
        • Biological Material Analytics
      • Department of Medical Bioinformatics
    • Halle (Saale) location
      • Department of Drug Design and Target Validation
        • Drugs and structural biology
        • Analytics
        • Pharmacology
        • Antibody technologies
    • Rostock location
      • Department of Extracorporeal Therapy Systems
    • Würzburg location
      • Department of Cellular Immunotherapy
    • Potsdam-Golm location
  • Central facilities
    [X] Central facilities
    • RIBOLUTION Biomarker Center
    • Center for Experimental Medicine
      • Preclinical models
    • GLP Test Facility
    • S3 safety laboratory
    • Advanced Analytics Technology Platform
      • Flow cytometry
      • Chromatography and Mass Spectrometry
      • Sequencing
      • Bioinformatics
      • Microscopy
      • Binding analytics
    • CIMD Biomaterial Bank
  • Press / media
    [X] Press / media
    • News and press releases
      • Development of therapeutic antibodies for HERV-associated autoimmune and tumor diseases
      • Hitchhiker’s Guide to the Cell: Fraunhofer IZI researches to improve imaging methods for organoids
      • Pathogen of Q fever detected in the feces of ticks
      • Professor Ulrich Demuth appointed to the German Ethics Council
      • Patented Fraunhofer IZI technology facilitates specific Dengue virus diagnostics
      • Astacin Proteases Unit established at Fraunhofer IZI
      • Prognostic biomarkers for prostate cancer identified
      • A chemical tailor-made suit for Alzheimer’s drugs
      • Fraunhofer relies on Automation Technologies in Medical Research
      • Fraunhofer IZI cooperates with Nomad Bioscience to develop novel anti-bacterial and anti-viral medications
      • Viromers suitable as carrier systems for gene-based treatment of inflammatory diseases
      • Fraunhofer IZI presents new technologies and services for the healthcare industry at the Fraunhofer Solution Days
      • Rapid diagnostic device for trachoma eye infection delivers first promising result
      • Optimization of novel immune cell therapies
      • SaxoCell – “living drug” Made in Saxony
      • Periodontitis: Researchers search for a new active substance
      • Fraunhofer Prize for Human- and Environment-Centered Technology 2021
      • Researchers aim at developing a vaccine protecting against urinary tract infection
      • Simplified method developed for monitoring CAR T-cell therapies using flow cytometry
      • Anhalt University of Applied Sciences and Fraunhofer IZI open joint research laboratory for natural product-based therapeutics
      • Researchers want to filter and inactivate airborne pathogens using tissue
      • Fraunhofer IZI and Nomad Bioscience extend and broaden collaboration
      • Outstanding bachelor thesis awarded
      • Fraunhofer opens up prospects in structurally weak regions
      • New Fraunhofer Center for Digital Diagnostics
      • Activation of the aryl hydrocarbon receptor (AhR) has an anti-inflammatory effect
      • Fraunhofer Center MEOS becomes technology hub for cell-based therapeutics in Thuringia
      • Fraunhofer IZI and BioNTech to collaborate in the future
      • Preclinical testing of a ATMP for the treatment of knee cartilage damage completed
      • Fraunhofer develops automated production technologies for mRNA-based drugs
      • REMEDi4ALL, an ambitious EU-funded research initiative, launches to drive forward the repurposing of medicines in Europe
      • Roadmap for future production of sufficient product numbers of cell-based cancer drugs
      • International research team elucidates molecular structure of Meprin alpha
      • Fraunhofer IZI implements digital Manufacturing Execution System
      • Hydrogels for tissue engineering
      • Software development expands portfolio of RIBOLUTION Biomarker Center at Fraunhofer IZI
      • GLP test facility of the Fraunhofer IZI certified for test category 2 since January 2023
      • Fraunhofer IZI contributes expertise to Germany's largest collaborative project on mosquito research
      • Symposium on the farewell of Professor Hans-Ulrich Demuth
      • Fraunhofer IZI supports the Czech Republic in establishing a research center for the development of novel cell and gene therapies
      • New strategies in the fight against the widespread disease periodontitis
      • Preclinical and clinical development of a novel CAR-T cell therapy for the treatment of multiple myeloma and clear cell renal cell carcinoma
      • Prof. Dr. Dr. Ulrike Köhl elected to the Saxon Academy of Sciences and Humanities in Leipzig
      • Fraunhofer IZI research project nominated for "HUGO JUNKERS PRIZE for Research and Innovation from Saxony-Anhalt"
      • Development and evaluation of an MRI-guided focused ultrasound system to improve radiation therapy for cancer
      • State government of Mecklenburg-Vorpommern supports research into extracorporeal therapy systems
      • Kick-off for the Central European Advanced Therapy and Immunotherapy Centre (CREATIC)
      • Doctoral scholarship for leukemia cell research
      • Joint appointment with Martin Luther University Halle-Wittenberg
      • Virtual twin to improve treatment with cancer immunotherapies
      • EU project investigates links between land use change, biodiversity loss and zoonosis risk
      • EU project promotes access to ATMPs and its use in clinical practice
      • New approach to early cancer detection honored with Hugo Geiger Prize
      • Fraunhofer IZI expands expertise in the field of cellular immunotherapy with new branch office in Würzburg
      • Biomarkers for the successful treatment of tumors in the bone marrow identified
      • Fraunhofer Institute for Cell Therapy and Immunology wins an award in the Mecklenburg-Vorpommern competition for ideas for the healthcare industry
      • New agent for the treatment of chronic inflammatory bowel diseases
      • Stephan Fricke appointed adjunct professor at Dresden Technical University (TUD)
      • SaxoCell future cluster starts second funding phase
      • QualiBioPharma qualification program honored as cluster success of the year 2024
      • Non-viral vectors for CAR-T cell therapy
      • Fraunhofer IZI relies on certified energy management
      • Recognition for our animal care: Fraunhofer IZI co-hosts the German TechWeek
      • Fraunhofer IZI’s founding director honored for his dedication to the city of Leipzig
      • Rare side effect after immunotherapy against cancer
      • Scientific conference highlights AAV technologies
      • Can bioactive components of breast milk support the prevention of infectious diseases?
      • Fraunhofer Institute for Cell Therapy and Immunology in Leipzig celebrates its 20th anniversary
      • First patient in LION-1 study receives immune cell therapy against new target molecule
      • Fraunhofer IZI Receives Seal for Exemplary Communication on Animal Research
      • Decentralized Manufacturing of CAR-T Cell Therapeutics
      • Prof. Dr. Stephan Fricke appointed Chair of Clinical Immunology and Cell Therapy at Magdeburg University Hospital
      • PlasmidFactory and Fraunhofer IZI join forces to advance non-viral cell and gene therapies
      • PD Dr. Sebastian Ulbert appointed Professor of Translational Infection Immunology at Leipzig University
      • Improved predictability of treatment outcomes and side effects of personalized cancer immunotherapies
      • Targeted inhibition of periodontitis pathogens
      • Innovative approach to minimising severe side effects after blood stem cell transplantation reaches important milestone
      • Dr. Kristin Reiche appointed Professor of Digital Molecular Medicine at IT:U
      • Accelerating the Development of Cell and Gene Therapies
    • Media Library
  • Events
  • Publications
  • Jobs / career
    [X] Jobs / career
    • What makes us special
    • Career starters and professionals
    • Pupils and students
    • Doctoral program
    • Cooperative course
    • Vocational training
    • FAQ
    • Work environments
  • Contact
    [X] Contact
    • How to reach us in Leipzig
    • How to reach us in Potsdam-Golm
    • How to reach us in Halle (Saale)
    • How to reach us in Rostock
  • More

    Document not found

    Navigation and Social Media

    Follow us

    • Contact
    • Publishing Notes
    • Data Protection
    © 2026

    Source: Fraunhofer-Gesellschaft
    Fraunhofer Institute for Cell Therapy and Immunology IZI - Errorpage 404

    Online in Internet; URL: https://www.izi.fraunhofer.de/en/error404.html

    Date: 1.4.2026 21:05